JP2015524422A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524422A5 JP2015524422A5 JP2015523550A JP2015523550A JP2015524422A5 JP 2015524422 A5 JP2015524422 A5 JP 2015524422A5 JP 2015523550 A JP2015523550 A JP 2015523550A JP 2015523550 A JP2015523550 A JP 2015523550A JP 2015524422 A5 JP2015524422 A5 JP 2015524422A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- set forth
- polypeptide
- sequence set
- respect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims 36
- 235000001014 amino acid Nutrition 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 238000006467 substitution reaction Methods 0.000 claims 17
- 241000725619 Dengue virus Species 0.000 claims 7
- 208000001490 Dengue Diseases 0.000 claims 6
- 206010012310 Dengue fever Diseases 0.000 claims 6
- 208000025729 dengue disease Diseases 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 230000002238 attenuated effect Effects 0.000 claims 3
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 3
- 241000710831 Flavivirus Species 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 241000710772 Yellow fever virus Species 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 229940051021 yellow-fever virus Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305908 | 2012-07-24 | ||
| EP12305908.1 | 2012-07-24 | ||
| EP12305911.5 | 2012-07-25 | ||
| EP12305911 | 2012-07-25 | ||
| PCT/EP2013/065669 WO2014016362A1 (en) | 2012-07-24 | 2013-07-24 | Vaccine compositions for prevention against dengue virus infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015524422A JP2015524422A (ja) | 2015-08-24 |
| JP2015524422A5 true JP2015524422A5 (cg-RX-API-DMAC7.html) | 2016-09-08 |
Family
ID=48856641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015523550A Pending JP2015524422A (ja) | 2012-07-24 | 2013-07-24 | ワクチン組成物 |
Country Status (15)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6818548B2 (ja) | 2013-03-15 | 2021-01-20 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | ワクチンにおけるデングウイルスキメラ構築物に関する組成物および方法 |
| JP2016523251A (ja) * | 2013-06-21 | 2016-08-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | デングウイルスワクチン組成物およびその使用方法 |
| TWI852899B (zh) * | 2014-09-02 | 2024-08-21 | 法商賽諾菲巴斯德公司 | 疫苗組合物 |
| EP3191589B1 (en) * | 2014-09-11 | 2025-11-26 | VLP Therapeutics, Inc. | Flavivirus virus like particle |
| AU2015369875A1 (en) * | 2014-12-22 | 2017-06-15 | Merck Sharp & Dohme Corp. | Dengue virus vaccine compositions and methods of use thereof |
| US10857222B2 (en) | 2015-07-03 | 2020-12-08 | Sanofi Pasteur | Concomitant dengue and yellow fever vaccination |
| EP3331559A4 (en) | 2015-08-03 | 2019-03-06 | The United States of America as represented by the Secretary of the Army, Walter Reed Army Institute Of Research (WRAIR) | IMMUNE-LEADING RECOMBINANT DENGUE PROTEIN |
| ES2974666T3 (es) * | 2015-09-29 | 2024-07-01 | Boehringer Ingelheim Animal Health Usa Inc | Vacunas de partículas similares a virus (VLP) del parvovirus canino (CPV) y usos de las mismas |
| WO2018208741A1 (en) | 2017-05-08 | 2018-11-15 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Methods and compositions for the detection of flavivirus infections |
| EP3691681A1 (en) | 2017-10-05 | 2020-08-12 | Sanofi Pasteur | Compositions for booster vaccination against dengu |
| CA3086456A1 (en) | 2017-12-21 | 2019-06-27 | Kirin Holdings Kabushiki Kaisha | Cross-immunizing antigen vaccine and method for preparation thereof |
| US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| PE20211545A1 (es) | 2018-09-05 | 2021-08-16 | Takeda Vaccines Inc | Dosis unitaria de vacuna contra el dengue y administracion de esta |
| US11426461B2 (en) | 2018-09-05 | 2022-08-30 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis A |
| US20220241359A1 (en) * | 2019-05-15 | 2022-08-04 | Codagenix Inc. | Attenuated yellow fever virus and uses thereof for the treatment of cancer |
| WO2025146159A1 (zh) * | 2024-01-05 | 2025-07-10 | 北京昌平实验室 | 针对寨卡/登革病毒的重组抗原、其疫苗组合物及其应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| FR2649012B1 (fr) | 1989-07-03 | 1991-10-25 | Seppic Sa | Emulsions multiphasiques injectables |
| FR2649013B1 (fr) | 1989-07-03 | 1991-10-25 | Seppic Sa | Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6254873B1 (en) | 1995-04-17 | 2001-07-03 | The United States Of America As Represented By The Secretary Of The Army | Inactivated dengue virus vaccine |
| WO1996040933A1 (en) | 1995-06-07 | 1996-12-19 | The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
| NZ337522A (en) | 1997-02-28 | 2001-02-23 | St | Chimeric flavivirus incorporating yellow fever virus modified such that a prM-E protein of a second flavivirus is expressed, and vaccines for flavivruses |
| GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
| GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
| WO1999011241A1 (en) | 1997-09-05 | 1999-03-11 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
| US7227011B2 (en) * | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
| WO2000057910A1 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Attenuated dengue-4 virus vaccine |
| EP1165128A2 (en) | 1999-03-26 | 2002-01-02 | Walter Reed Army Institute of Research | Attenuated dengue-2 virus vaccine |
| EP1165130A2 (en) | 1999-03-26 | 2002-01-02 | Walter Reed Army Institute of Research | Attenuated dengue-3 virus vaccine |
| AU4179200A (en) | 1999-03-26 | 2000-10-16 | Walter Reed Army Institute Of Research | Attenuated dengue-1 virus vaccine |
| WO2001009309A2 (en) * | 1999-08-02 | 2001-02-08 | American Home Products Corporation | RESCUE OF MUMPS VIRUS FROM cDNA |
| EP1263965B1 (en) | 2000-02-16 | 2011-09-28 | The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services | Avirulent, immunogenic flavivirus chimeras |
| DK1159968T3 (da) | 2000-05-30 | 2009-02-23 | Univ Mahidol | Attenuerede stammer af Dengue-virus og deres anvendelse i en vaccinesammensætning |
| AT410634B (de) | 2001-02-21 | 2003-06-25 | Franz X Dr Heinz | Attenuierte lebendimpfstoffe |
| KR20040004642A (ko) | 2001-05-23 | 2004-01-13 | 덴드레온 샌 디에고 엘엘씨 | 세포 표면 프로테아제에 의해 활성화되는 접합체 및 이의치료학적 용도 |
| PL371187A1 (en) * | 2001-06-01 | 2005-06-13 | Acambis, Inc. | Chimeric flavivirus vectors |
| AU2002330672A1 (en) | 2001-07-25 | 2003-02-17 | Genset S.A. | Gmg-1 polynucleotides and polypeptides and uses thereof |
| DK2338508T3 (en) * | 2002-05-03 | 2018-05-28 | The Government Of The Us Secretary Department Of Health And Human Services | rDEN3 / 4delta30 (ME), rDEN2 / 4delta30 (ME) or rDEN1 / 4delta30 (ME) recombinant chimeric Dengue virus containing a 30 nucleotide deletion (delta30) in a section of the 3 'untranslated region of Dengue type 4 genome, where The 30-nucleotide deletion corresponds to the TL2 hairpin structure |
| WO2003101397A2 (en) | 2002-05-31 | 2003-12-11 | Acambis, Inc. | Tetravalent dengue vaccines |
| CN1852734B (zh) * | 2003-09-17 | 2010-12-01 | 杜克大学 | 共有/祖先免疫原 |
| ATE475706T1 (de) * | 2005-06-17 | 2010-08-15 | Sanofi Pasteur | Abgeschwächter dengue-serotyp-2-stamm |
| CA2611934C (en) * | 2005-06-17 | 2015-11-03 | Sanofi Pasteur | Dengue serotype 1 attenuated strain |
| AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
| JP5227172B2 (ja) | 2005-08-10 | 2013-07-03 | サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー | デングウイルス感染に対するワクチン接種 |
| CU23586A1 (es) * | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
| FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| US7968102B2 (en) * | 2006-01-13 | 2011-06-28 | Sanofi Pasteur S.A. | Dengue chimeric viruses |
| FR2903605A1 (fr) | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| FR2906724B1 (fr) | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| FR2909286B1 (fr) | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
| WO2008115314A2 (en) * | 2007-01-31 | 2008-09-25 | Sanofi Pasteur Biologics Co. | Flavivirus vaccine vector against influenza virus |
| AU2009241354B2 (en) * | 2008-04-30 | 2014-06-12 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Chimeric West Nile/Dengue viruses |
| EP2143440A1 (fr) | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
| CN106421743A (zh) * | 2009-07-29 | 2017-02-22 | 贝恩德·赫尔穆特·阿达姆·雷姆 | 聚合物微粒及其用途 |
| US8900596B2 (en) * | 2009-11-18 | 2014-12-02 | The Board Of Regents Of The University Of Texas System | Physicochemical (PCP) based consensus sequences and uses thereof |
| GB201007531D0 (en) | 2010-05-05 | 2010-06-23 | Imp Innovations Ltd | Composition |
| CN102906266A (zh) * | 2010-05-21 | 2013-01-30 | 高等教育联邦系统-匹兹堡大学 | 登革病毒通用序列及其使用方法 |
| WO2012051491A1 (en) * | 2010-10-14 | 2012-04-19 | The United States Of America, As Represented By The Secretary National Institutes Of Health | Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting |
| US20150196631A1 (en) * | 2012-07-24 | 2015-07-16 | Sanofi Pasteur | Vaccine compositions |
-
2013
- 2013-07-24 PE PE2015000070A patent/PE20150356A1/es not_active Application Discontinuation
- 2013-07-24 AU AU2013295016A patent/AU2013295016A1/en not_active Abandoned
- 2013-07-24 JP JP2015523550A patent/JP2015524422A/ja active Pending
- 2013-07-24 US US14/416,492 patent/US20150265695A1/en not_active Abandoned
- 2013-07-24 MX MX2015000446A patent/MX2015000446A/es unknown
- 2013-07-24 CN CN201380049741.2A patent/CN104812408A/zh active Pending
- 2013-07-24 HK HK16100914.5A patent/HK1212905A1/zh unknown
- 2013-07-24 WO PCT/EP2013/065669 patent/WO2014016362A1/en not_active Ceased
- 2013-07-24 SG SG11201500439RA patent/SG11201500439RA/en unknown
- 2013-07-24 KR KR20157003822A patent/KR20150036593A/ko not_active Withdrawn
- 2013-07-24 EP EP13740025.5A patent/EP2877207A1/en not_active Withdrawn
- 2013-07-24 BR BR112015001313A patent/BR112015001313A2/pt not_active IP Right Cessation
- 2013-07-24 CA CA2878599A patent/CA2878599A1/en not_active Abandoned
-
2014
- 2014-12-23 PH PH12014502875A patent/PH12014502875A1/en unknown
-
2015
- 2015-01-12 GT GT201500005A patent/GT201500005A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015524422A5 (cg-RX-API-DMAC7.html) | ||
| CY1124202T1 (el) | Εμβολια ανασυνδυασμενου zika | |
| JP2014502156A5 (cg-RX-API-DMAC7.html) | ||
| WO2014018858A3 (en) | Multimeric fusion protein vaccine and immunotherapeutic | |
| EP3199545A3 (en) | Computationally optimized broadly reactive antigens for h1n1 influenza | |
| JP2014000092A5 (cg-RX-API-DMAC7.html) | ||
| WO2012106377A3 (en) | Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof | |
| JP2017526689A5 (cg-RX-API-DMAC7.html) | ||
| WO2017015463A3 (en) | Infectious disease vaccines | |
| JP2013517773A5 (cg-RX-API-DMAC7.html) | ||
| JP2015533841A5 (cg-RX-API-DMAC7.html) | ||
| JP2014534202A5 (cg-RX-API-DMAC7.html) | ||
| JP2014530010A5 (cg-RX-API-DMAC7.html) | ||
| RU2015135890A (ru) | Композиция вакцины | |
| JP2011530309A5 (cg-RX-API-DMAC7.html) | ||
| SG10201903538YA (en) | Modified virus-like particles of cmv | |
| WO2010057159A3 (en) | Antigens that elicit immune response against flavivirus and methods of using same | |
| JP2016533332A5 (cg-RX-API-DMAC7.html) | ||
| RU2015138530A (ru) | Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа | |
| PH12015500308B1 (en) | Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same | |
| CL2012000447A1 (es) | Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica. | |
| MX359981B (es) | Virus de sarampión recombinante que expresa polipéptidos del virus de chinkunguña, y sus aplicaciones. | |
| MX343830B (es) | Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma. | |
| HK1203524A1 (en) | Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses | |
| JP2018531624A5 (cg-RX-API-DMAC7.html) |